<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:department>Centre for Cancer Res and Cell Biology</gtr:department><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/AE727DEA-B081-402C-8320-ADF1A6C8C374"><gtr:id>AE727DEA-B081-402C-8320-ADF1A6C8C374</gtr:id><gtr:firstName>Jacqueline</gtr:firstName><gtr:surname>James</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/92124212-FC14-4902-9BC3-A431AD029474"><gtr:id>92124212-FC14-4902-9BC3-A431AD029474</gtr:id><gtr:firstName>Dennis</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>McCance</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4D4DD685-0213-47A7-8778-2F0E388B8CC9"><gtr:id>4D4DD685-0213-47A7-8778-2F0E388B8CC9</gtr:id><gtr:firstName>Daksha</gtr:firstName><gtr:surname>Patel</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1001692"><gtr:id>2BE92D00-F4C5-4F58-A48E-0FA8B9FFB185</gtr:id><gtr:title>The role of p63 isoforms in head and neck cancers</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1001692</gtr:grantReference><gtr:abstractText>When normal cells become cancerous they go through a phase called epithelial to mesenchymal transition (EMT) which allows the cells to invade into other tissues. EMT also occurs during embryogenesis but here it is tightly controlled. We wish to study this process in oro-pharyngeal cancers which are cancers at the back of the oral cavity and are associated with infection by the human papillomaviruses (HPV) that cause genital cancers. It has recently been observed that patients with oro-pharyngeal cancer which contain HPV live longer than people whose cancers are HPV negative. We propose that the difference is due to the regulation of EMT, which we have shown can be controlled by p63, a family of proteins that are important for EMT during organ development. Our theory is the increased levels of p63 observed in HPV cancers protect against EMT and may contribute to the better prognosis seen in HPV positive cancers.</gtr:abstractText><gtr:technicalSummary>Head and neck cancers, in particular oro-pharyngeal cancers, are on the increase in a population of patients who do not have the usual demographics of, elderly male with a history of smoking and heavy alcohol consummation. The increase is thought to be due, in part, to increased infection with human papillomavirus (HPV) type 16 which is found in 20 to 40% of cases. The HPV positive cancers have a better prognosis than HPV negative ones, although the reasons behind this outcome are unknown. Epithelial to mesenchymal transition (EMT) is a normal process in development, but also occurs in cancers during invasion and metastasis. p63, a member of the p53 family of transcription factors, has multiple isoforms. We have found that some of these isoforms inhibit EMT, while others potentiate EMT. The TGF-beta pathway is important in EMT and also carcinogenesis and we have found that the TGF-beta gene is regulated by certain p63 isoforms. The isoforms deltaNp63alpha and deltaNp63beta inhibit EMT, while deltaNp63gamma stimulates EMT through its regulation of the TGF-beta gene and perhaps other genes in the TGF-beta pathway. HPV proteins up-regulate p63 isoforms at the transcriptional and post transcriptional level and our hypothesis is that this up-regulation protects HPV positive cancers from the growth potentiating effects of TGF-beta , resulting in a better prognosis. To widen these studies and determine at a global level the genes regulated by p63 isoforms, we have carried out ChIP-seq experiments to determine potential p63 binding sites. We have validated a number of genes that are involved in EMT during normal tissue development and we want to determine if they have a role in oro-pharyngeal cancers. We will initially determine what p63 isoforms are expressed in HPV positive and negative oro-pharyngeal cancers, then investigate the differential functions of p63 isoforms and the consequences of their disruption and finally elucidate the role of the genes involved in tissue EMT during development.</gtr:technicalSummary><gtr:fund><gtr:end>2015-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>895374</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E78A1479-87D6-4BBA-B9A3-6D10A7AFBD94</gtr:id><gtr:title>HPV16 Down-Regulates the Insulin-Like Growth Factor Binding Protein 2 to Promote Epithelial Invasion in Organotypic Cultures.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da58a9d15121898145444662693bb6dd"><gtr:id>da58a9d15121898145444662693bb6dd</gtr:id><gtr:otherNames>Pickard A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>5675e73b0a1d9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF605443-4D7F-4EDF-9815-3C94BCB17B99</gtr:id><gtr:title>Genome-wide characterization reveals complex interplay between TP53 and TP63 in response to genotoxic stress.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5ce6a0c6bea1768a11f3f2f21be6069"><gtr:id>a5ce6a0c6bea1768a11f3f2f21be6069</gtr:id><gtr:otherNames>McDade SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>pm_540e176e17671512d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>57EFAB9B-7200-4D45-B612-D1941D67CA20</gtr:id><gtr:title>p63 drives invasion in keratinocytes expressing HPV16 E6/E7 genes through regulation of Src-FAK signalling.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b24f1242edd09e829b2f2415df923c0"><gtr:id>2b24f1242edd09e829b2f2415df923c0</gtr:id><gtr:otherNames>Srivastava K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>56cf286f3e5677.61503999</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>031C0B79-20F7-44BE-86ED-0C209233E914</gtr:id><gtr:title>IGF-Binding Protein 2 - Oncogene or Tumor Suppressor?</gtr:title><gtr:parentPublicationTitle>Frontiers in endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da58a9d15121898145444662693bb6dd"><gtr:id>da58a9d15121898145444662693bb6dd</gtr:id><gtr:otherNames>Pickard A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1664-2392</gtr:issn><gtr:outcomeId>56cf28a8d5c049.17257548</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15D4192F-4A37-4EA3-8F5B-1798265F5E6D</gtr:id><gtr:title>Genome-wide analysis of p63 binding sites identifies AP-2 factors as co-regulators of epidermal differentiation.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5ce6a0c6bea1768a11f3f2f21be6069"><gtr:id>a5ce6a0c6bea1768a11f3f2f21be6069</gtr:id><gtr:otherNames>McDade SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>pm_12972_22_22573176</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47BF0370-C4E8-44B9-AF28-91C2017A03C1</gtr:id><gtr:title>AKT in stromal fibroblasts controls invasion of epithelial cells.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/05bc32acc3a5a5c5e7c4b7efaf91cd61"><gtr:id>05bc32acc3a5a5c5e7c4b7efaf91cd61</gtr:id><gtr:otherNames>Cichon AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>pm_12972_22_23867201</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1001692</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>